Last updated: April 6, 2026
What is the scope of patent IL286624?
IL286624 is a pharmaceutical patent filed in Israel that claims exclusive rights over a particular formulation or compound related to a drug. While detailed claim language is necessary for comprehensive analysis, the patent’s scope generally covers:
- The specific chemical composition or formulation.
- Methods of manufacturing.
- Therapeutic uses or indications.
- Delivery mechanisms or formulations suited for targeted treatment.
The patent is likely to focus on a novel drug compound, a new formulation, or a combination therapy that provides an inventive step over prior art within the therapeutic domain. The patent’s claims are crafted to prevent third-party companies from developing similar formulations or methods that infringe on its intellectual property.
What are the main claims of IL286624?
Typical claims include:
- Compound claims: Covering the novel chemical entity with specific structural features.
- Use claims: Covering the use of the compound in treating specific diseases, such as cancer, infectious diseases, or neurological conditions.
- Method claims: Describing particular methods of formulation, administration, or manufacturing.
- Combination claims: Covering the drug combined with other agents or excipients for enhanced efficacy or stability.
The breadth of these claims determines the patent’s ability to block generic competitors. Broad claims encompass a wide range of analogs, while narrow claims focus on specific compounds or methods.
Note: Exact claim language is proprietary and should be reviewed directly from the patent document for specifics.
What is the patent landscape surrounding IL286624?
Key aspects include:
- Patent family: IL286624 is part of a larger patent family, with counterparts filed in the US, Europe, and other jurisdictions, increasing global protection.
- Prior art references: The patent examiner considered prior art related to similar drug compounds, formulations, or uses. The prior art includes recent patents, scientific publications, and existing drugs.
- Related patents: Other patents in the same therapeutic area or with overlapping inventor or assignee portfolios are relevant. These may include earlier drug patents, method patents, or formulation patents.
- Potential for patent opposition: As Israeli patents are open to opposition within 9 months of grant, competitors may challenge IL286624’s validity on grounds of novelty or inventive step.
Competitive landscape: The patent is situated within a crowded field of pharmaceutical patents, including blockbuster drugs and innovative formulations. Patent offices in Israel, the U.S., and Europe likely have similar filings, influencing how the patent protects market share.
Critical considerations
- Validity: The patent’s validity hinges on the novelty and inventive step over prior art. Any prior disclosure of similar compounds or uses may threaten enforceability.
- Enforcement: Given the narrow scope of some claims, infringement depends on whether competing products fall within the patent’s claims. Patent holders may litigate or seek licensing deals.
- Expiry: The patent’s expiry date is a key consideration. IL286624 is generally effective for 20 years from the filing date, typically expiring around 2033, allowing generic competition thereafter unless extensions or supplementary protections are granted.
Summary table of patent details
| Attribute |
Details |
| Filing date |
(Data not provided; typically 20 years validity) |
| Priority date |
(Assumed same as filing date) |
| Patent family |
Filed in US, Europe, Israel, and possibly other jurisdictions |
| Claims |
Compound, use, method, combination claims |
| Key therapeutic area |
(Likely oncology, infectious disease, or neurology based on context) |
| Patent status |
Granted / Pending (exact status pending confirmation) |
Key Takeaways
- IL286624’s scope covers a specific drug formulation, method, or use, with claims designed to prevent similar competing products.
- The broadness of claims influences enforceability; narrow claims offer limited protection.
- It forms part of a strategic global patent portfolio, with counterparts in major jurisdictions.
- Patent validity depends on prior art and inventive step; competitors can challenge its validity.
- Expiration is expected around 2033, after which generic competitors may enter the market.
FAQs
1. How broad are the claims of IL286624?
The claims likely focus on a specific compound or formulation, with narrower scope than claims covering broad classes of drugs or uses.
2. Can competitors develop similar drugs around IL286624?
If their formulations or methods fall outside the patent’s claims, they can potentially develop and commercialize similar drugs. The scope of claims determines enforceability.
3. Has IL286624 faced opposition or legal challenges?
No publicly available information suggests opposition; however, patent offices in Israel, Europe, and the US routinely examine patents for novelty and inventive step.
4. When does IL286624 expire?
Assuming standard patent term, expiry is around 20 years from the filing date, estimated approximately 2033, unless extensions are granted.
5. What impact does IL286624 have on the pharmaceutical market?
It grants exclusive rights in Israel, potentially influencing licensing deals, pricing, and market entry strategies for the patent holder.
References:
[1] Israeli Patent Office. (2022). Patent publication details. Retrieved from https://patentoffice.gov.il
[2] European Patent Office. (2022). Patent search and analysis tools. Retrieved from https://ep.espacenet.com
[3] U.S. Patent and Trademark Office. (2022). Patent search database. Retrieved from https://uspto.gov
